SYN X makes progress with CHF (congestive heart failure) and Alzheimer's tests
This article was originally published in Clinica
Executive Summary
SYN X Pharma has received an allowance for US patent for a 15-minute, point-of-care test for congestive heart failure (CHF). The test, claimed the firm, is the first to combine, in a single test, two known methods for diagnosing the disease - a marker for myocardial cell injury and a marker for left ventricular overload. Together these indicators for dying cells and heart enlargement provide more accurate patient prognosis, said Toronto, Canada based SYN X.